NY-ESO-1 protein cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by poly-ICLC
We conducted a clinical trial of a cancer vaccine using NY-ESO-1 protein with polyinosinic-
polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against
solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort
1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+ OK-432; cohort 2b
received NY-ESO-1 protein+ poly-ICLC; cohort 3 received NY-ESO-1 protein+ OK-432+ poly-
ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune …
polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC) and/or OK-432 against
solid tumors. A total of 15 patients were sequentially enrolled in 4 cohorts. Patients in cohort
1 received NY-ESO-1 protein; cohort 2a received NY-ESO-1 protein+ OK-432; cohort 2b
received NY-ESO-1 protein+ poly-ICLC; cohort 3 received NY-ESO-1 protein+ OK-432+ poly-
ICLC with Montanide ISA-51. The endpoints of this trial were safety, NY-ESO-1 immune …